PPD Opens Global Central Lab in Singapore

Image
Announcement Corporate
Last Updated : Jan 20 2013 | 12:09 AM IST

Offers a comprehensive suite of highly customized services

PPD, Inc. (Nasdaq: PPDI) announced it has opened its global central lab facility in Singapore, strengthening its ability to provide biopharmaceutical clients an extensive range of customized laboratory services in Southeast Asia, a high-growth region for clinical research.

"Expanding our global central lab services into Singapore demonstrates our commitment to deliver high quality specimens and laboratory results for our clients in a growing biopharmaceutical market," said Steve Lobel, vice president, global laboratory operations, PPD. "We can expedite delivery of lab data through reduced transportation and shipping time at better logistics costs for our clients."

PPD also has an office in Singapore, where for more than 10 years it has provided a range of clinical development services, including clinical trial management and monitoring, patient recruitment, site identification and regulatory affairs.

The laboratory instrumentation and standards in Singapore are identical to platforms located at PPD's global central labs in Brussels, Belgium; Highland Heights, Ky.; and Beijing, China. Assays are extensively cross validated among all PPD locations to produce combinable data. The Singapore lab interfaces directly with ConneXion, the company's proprietary single global database, to ensure consistent management and real-time reporting. Clients can view and analyze laboratory results from all lab locations using PPD Clicks™, a secure Web site launched last year.

PPD's lab is located at 61 Science Park Road #02-12/14, Singapore Science Park II Singapore 117525. For more information about PPD's global central lab capabilities, contact Dean Hass, vice president, business development, at +1 913 681 5854 or at dean.hass@ppdi.com.

PPD is a leading global contract research organization providing discovery, development and post-approval services as well as compound partnering programs. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 38 countries and more than 10,000 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a commitment to quality to help its clients and partners maximize returns on their R&D investments and accelerate the delivery of safe and effective therapeutics to patients. For more information, visit our Web site at http://www.ppdi.com

 

 

 

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Sep 24 2009 | 12:51 PM IST

Next Story